← boardnext 2026-08
SLGL
Sol-Gel Technologies, Ltd.distress 1/10 · well-funded / low risk$84.300%today-14% from 52w high
Lead: Gorlin Syndrome
Revenue
$19M
Liquidity
$24M
Runway
—
Shares 1y
0%
Price & events
+46.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+8.0%
1W
+18.3%
1M
+16.6%
3M
+44.3%
6M
+748.1%
1Y
+1087.3%
2Y
-30.3%
5Y
-15.1%
All
Overview
- Market Cap
- $234.87M
- Volume
- 1.98K
- 52 Week Range
- $8.02 – $97.97
- Total Shares
- 2.79M
- Float Shares
- 530.07K
- Short %
- 4.51%
- % Held by Insiders
- 59.70%
- % Held by Institutions
- 37.32%
- RVOL
- 0.06x
- Beta
- 1.13
Pipeline stages · 1 programs
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib | Gorlin Syndrome | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-08-21Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $193 (+129% upside) · 3 analysts
- 2026-07-20HC Wainwright & Co.Buy
- 2026-06-24MizuhoOutperform
- 2026-01-20HC Wainwright & Co.Buy
- 2025-12-22HC Wainwright & Co.Buy
- 2025-10-27HC Wainwright & Co.Buy
- 2024-08-19Raymond JamesStrong Buy → Outperform
Competitors — Gorlin Syndrome
- INTIInhibitor Therapeutics, Inc.$13M · D5
Recent news
- 2026-07-20SLGL Reiterated by HC Wainwright & Co. -- Rating Remains Buy - GuruFocus
- 2026-07-15Sol-Gel Technologies (NASDAQ: SLGL) holder adds 1,695 shares - Stock Titan
- 2026-07-10Opaleye Management (SLGL) adds Sol-Gel stake with open-market share purchases - Stock Titan
- 2026-07-07SLGL Q1 2026 Earnings: Narrower Net Loss Beats Street Estimates Despite No Revenue - Diluted EPS Report - dars.gov.et
- 2026-07-02Opaleye boosts Sol-Gel (SLGL) stake with 1,712-share open-market buy - Stock Titan
- 2026-06-25SLGL Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-16Sol-Gel Technologies (SLGL) Faces Slight Pullback Near Resistance - Advance Decline Volume - dars.gov.et
- 2026-05-28Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.